EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Recipient Versus Donor CYP3A4/5 Genotypes in Adult Liver Transplant Recipients to Achieve Therapeutic Tacrolimus Concentrations Early Post‐Transplant

Eda Eken iD, Sergio Duarte iD, Isabella Angeli-Pahim iD, Alexandra D Ladd iD, Curtis Warren iD, Taimour Y Langaee iD, Ali Zarrinpar iD, Julie A Johnson iD

Clinical and Translational Science · 2025-09 · 18 (9)

DOI: 10.1111/cts.70329 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Translational Science, online erschienen am 29.08.2025. Verfasst von Eda Eken und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Tacrolimus, Liver Transplantation, Cytochrome P-450 CYP3A, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tacrolimus is an immunosuppressive agent with difficult dosing due to a narrow therapeutic index and large interpatient pharmacokinetic variability, for which CYP3A5 variation plays a role. Tacrolimus/ CYP3A5 pharmacogenetic guidelines exclude liver transplant patients with a donor/recipient CYP3A5 mismatch. We sought to determine the influence of donor vs. recipient CYP3A5 genotype early post‐transplant and evaluate tacrolimus dosing strategies in liver transplant recipients with various recipient/donor CYP3A5 genotype combinations. This was a single‐center, retrospective analysis of 58 prospectively enrolled adult liver transplant patients prescribed tacrolimus post‐transplant, with donor and recipient CYP3A5 genotype data, which were categorized as recipient expresser (RE) or nonexpresser (RN) and donor expresser (DE) or nonexpresser (DN). Patients were stratified as REDE, REDN, RNDN, or RNDE with comparisons across groups. Prediction error (PE) based on predicted versus actual therapeutic dose was calculated for eight published dosing methods. Donor/recipient genotype was mismatched in 41% of liver transplant recipients. Weight‐adjusted total daily dose for first therapeutic tacrolimus concentration was significantly different across CYP3A5 combinations, with recipient expressors requiring the highest doses (REDE 0.15 mg/kg/day, REDN 0.19 mg/kg/day, RNDE 0.12 mg/kg/day, RNDN 0.09 mg/kg/day, p = 0.006). Of the eight dosing methods analyzed, two performed with < 2% PE overall, and ≤ 20% PE for all four genotype combinations: one included recipient genotype only; the other included donor and recipient genotype. Collectively, our findings suggest recipient CYP3A5 genotype may be more important than donor genotype in the immediate post‐liver transplant period for predicting optimal tacrolimus dosing to achieve therapeutic trough concentrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusLiver TransplantationCytochrome P-450 CYP3AImmunosuppressive AgentsGraft RejectionHumansMaleMiddle AgedFemaleAdultRetrospective StudiesTissue DonorsGenotypeTransplant RecipientsAgedProspective StudiesDose-Response Relationship, Drug

Stichwörter der Autor:innen

CYP3A5Prografliver transplantpharmacogeneticspharmacogenomicsprecision medicinetacrolimus

Substanzen

TacrolimusCytochrome P-450 CYP3ACYP3A5 protein, humanImmunosuppressive AgentsCYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Surgery, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, University of South Florida, Tampa, Florida, USA.
  • Department of Internal Medicine and Pharmaceutics and Pharmacology, Colleges of Medicine and Pharmacy and Clinical and Translational Science Institute, The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Eda Eken, Sergio Duarte, Isabella Angeli-Pahim, Alexandra D Ladd, Curtis Warren, Taimour Y Langaee, Ali Zarrinpar, Julie A Johnson

Zitieren

APA

Eken, E., Duarte, S., Angeli-Pahim, I., Ladd, A. D., Warren, C., Langaee, T. Y., Zarrinpar, A., & Johnson, J. A. (2025). Recipient Versus Donor CYP3A4/5 Genotypes in Adult Liver Transplant Recipients to Achieve Therapeutic Tacrolimus Concentrations Early Post‐Transplant. Clinical and Translational Science, 18(9). https://doi.org/10.1111/cts.70329

Vancouver

Eken E, Duarte S, Angeli-Pahim I, Ladd AD, Warren C, Langaee TY, et al. Recipient Versus Donor CYP3A4/5 Genotypes in Adult Liver Transplant Recipients to Achieve Therapeutic Tacrolimus Concentrations Early Post‐Transplant. Clinical and Translational Science. 2025;18(9). doi:10.1111/cts.70329

BibTeX
@article{Eken2025,
  author = {Eken, Eda and Duarte, Sergio and Angeli-Pahim, Isabella and Ladd, Alexandra D and Warren, Curtis and Langaee, Taimour Y and Zarrinpar, Ali and Johnson, Julie A},
  title = {Recipient Versus Donor CYP3A4/5 Genotypes in Adult Liver Transplant Recipients to Achieve Therapeutic Tacrolimus Concentrations Early Post‐Transplant},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {9},
  doi = {10.1111/cts.70329}
}
Kostenlos starten →